Oxygen flux rates were normalized to mg of protein added determined with a BCA protein analysis test (Pierce)
10.1016/j.phymed.2012.04.006 55 EstrelaJ
Andreazza AC, Kauer-Santanna M, Frey BN, Bond DJ, Kapczinski F, Young LT et al
However, a 2015 meta-analysis, comparing cancer risk in 11 phase III trials between different available DMTs at the time, including GA, natalizumab, dimethyl fumerate, tefiluonomide, and fingolimod, demonstrated that there was not a higher cancer risk in MS patients who were treated with cladribine, but rather that due to a placebo comparator, there was an exaggerated relative increased risk in the treatment groups (151)
in Special Cytology